India, Aug. 28 -- Aprea Therapeutics, Inc. (APRE), a clinical-stage precision medicine oncology company focused on targeted therapies for biomarker-defined cancers, announced an expansion of its global intellectual property portfolio covering its WEE1 and ATR inhibitor programs.
Aprea's intellectual property portfolio now includes 28 issued patents and 30 pending patent applications across the U.S. and international markets.
The company's WEE1 kinase inhibitor program is protected by two pending U.S. patent applications, one pending U.S. provisional application, two granted non-U.S. patents and 12 pending non-U.S. patent applications.
The WEE1 patent portfolio covers proprietary compounds, pharmaceutical compositions and methods of use....